| Description | L-Phenylalanine-15N ((S)-2-Amino-3-phenylpropionic acid-15N) is the 15N-labeled L-Phenylalanine. L-Phenylalanine is an essential amino acid isolated from Escherichia coli . L-Phenylalanine is a α2δ subunit of voltage-dependent Ca + channels antagonist with a K i of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) ( K B of 573 μM ) and non-NMDARs , respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals. |
| In vitro | 将氢、碳等元素的稳定重同位素整合入化合物中，主要用作药物开发过程中的示踪剂以进行量化。涉及用氘标记的药物在人体中使用的研究表明，与非氘代药物相比，这些化合物可能提供一些优势。由于可能影响药物的药代动力学和代谢特性，氘代引起了广泛关注。 |
| Synonyms | L-苯丙氨酸 15N, (S)-2-Amino-3-phenylpropionic acid-15N, L-Phenylalanine-15N |
| molecular weight | 166.18 |
| Molecular formula | C9H11NO2 |
| CAS | 29700-34-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: < 1.66 mg/mL (10 mM, insoluble or slightly soluble) |
| References | 1. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. 2. Wu WB, et al. Enhancement of l-phenylalanine production in Escherichia coli by heterologous expression of Vitreoscilla hemoglobin. Biotechnol Appl Biochem. 2018 May;65(3):476-483. 3. Mortell KH, et al. Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. 4. Glushakov AV, et al. Specific inhibition of N-methyl-D-aspartate receptor function in rat hippocampal neurons by L-phenylalanine at concentrations observed during phenylketonuria. Mol Psychiatry. 2002;7(4):359-67. 5. Glushakov AV, et al. L-phenylalanine selectively depresses currents at glutamatergic excitatory synapses. J Neurosci Res. 2003 Apr 1;72(1):116-24. 6. Glushakov AV, et al. Long-term changes in glutamatergic synaptic transmission in phenylketonuria. Brain. 2005 Feb;128(Pt 2):300-7. |